Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review

Bona, Danilo Di; Plaia, Antonella; Leto-Barone, Maria Stefania; Piana, Simona La; Macchia, Luigi; Lorenzo, Gabriele Di

doi:10.1111/all.13104

Cited by 61 publications

(38 citation statements)

References 48 publications

(170 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For pollen allergies, a rush schedule achieved efficacy even with intraseasonal application, although local adverse reactions were over 40% . There is low‐grade evidence that AIT could prevent new allergen sensitizations in people . In human AD, there is only inconclusive evidence for the efficacy of SCIT .…”

Section: Subcutaneous Allergen Immunotherapy (Scit)mentioning

confidence: 99%

Allergen immunotherapy in people, dogs, cats and horses – differences, similarities and research needs

Mueller¹,

Jensen‐Jarolim

Roth‐Walter

et al. 2018

Allergy

View full text Add to dashboard Cite

In human patients with seasonal allergic rhinoconjunctivitis sensitized to grass pollen, the first successful allergen immunotherapy (AIT) was reported in 1911. Today, immunotherapy is an accepted treatment for allergic asthma, allergic rhinitis and hypersensitivities to insect venom. AIT is also used for atopic dermatitis and recently for food allergy. Subcutaneous, epicutaneous, intralymphatic, oral and sublingual protocols of AIT exist. In animals, most data are available in dogs where subcutaneous AIT is an accepted treatment for atopic dermatitis. Initiating a regulatory response and a production of "blocking" IgG antibodies with AIT are similar mechanisms in human beings and dogs with allergic diseases. Although subcutaneous immunotherapy is used for atopic dermatitis in cats, data for its efficacy are sparse. There is some evidence for successful treatment of feline asthma with AIT. In horses, most studies evaluate the effect of AIT on insect hypersensitivity with conflicting results although promising pilot studies have demonstrated the prophylaxis of insect hypersensitivity with recombinant antigens of biting midges (Culicoides spp.). Optimizing AIT using allergoids, peptide immunotherapy, recombinant allergens and new adjuvants with the different administration types of allergen extracts will further improve compliance and efficacy of this proven treatment modality.

show abstract

Section: Subcutaneous Allergen Immunotherapy (Scit)mentioning

confidence: 99%

Allergen immunotherapy in people, dogs, cats and horses – differences, similarities and research needs

Mueller¹,

Jensen‐Jarolim

Roth‐Walter

et al. 2018

Allergy

View full text Add to dashboard Cite

show abstract

“…Thus, we suggest that the genetic predisposition is the most prominent factor in developing new sensitizations. A recent review has already reported that the available evidence supporting the notion that SIT is effective in reducing the development of new allergen sensitizations in allergic mono-or polisensitized patients is low in strength (19).…”

Section: Discussionmentioning

confidence: 99%

Does Allergen-Specific Immunotherapy Prevent New Sensitizations in Childhood Allergic Airway Diseases?

Dilek

Bağ

Altınöz

et al. 2017

Asthma Allergy Immunol

View full text Add to dashboard Cite

ÖZAmaç: Spesifik immünoterapi (SIT) allerjik hastalıkların tedavisinde yer alan ve hastalığın doğal gidişini değiştirme potansiyeli olan bir tedavi yöntemidir. Mekanizması tam olarak bilinmemekle birlikte, son yıllarda yeni allerjik duyarlanmaları önleyebileceği yönünde çalışmalar bildirilmektedir. Çalışmanın amacı, allerjik hava yolu hastalığı olan çocuk hastalarda, SIT sonrası yeni duyarlanma gelişimi arasındaki ilişkinin değerlendirilmesidir. Gereç ve Yöntem:Bu retrospektif kesitsel araştırma, Dr. Behçet Uz Çocuk Hastanesinde allerjik rinit ve/veya astım nedeniyle izlenmekte olan monosensitize çocuk olgular ile planlandı. İzlemde, SIT önerilen ve kabul ederek uygulanmış olan olgular SIT grubunu (n:67), kabul etmeyerek medikal tedaviyle izlenmiş olan olgular ise kontrol grubunu (n:57) oluşturdu. Tanı sırasında deri testinde saptanmayan ve tedavi sonunda gelişmiş olan allerjik duyarlanmalar 'yeni duyarlanma' olarak kabul edildi. Bulgular: SIT grubu (yaş ortalaması: 15.27±3.15; E/K: 42/25) ile kontrol grubu (yaş ortalaması: 12.61 ± 2.69) yaş, cinsiyet ve allerjik hava yolu hastalığının dağılımı ve mevcut hava yolu allerjeni açısından benzerdi (p>0.05). İzlem süresi sonunda saptanan yeni duyarlanma oranı SIT grubunda (26/67)%38.8 olarak saptanırken, kontrol grubunda (14/57) %24.6 olarak tespit edildi. Bu fark istatistiksel olarak anlamlı değildi (p:0.12). Çalışma grubunda en sık gelişen yeni duyarlanmanın ot polenleri (12/40), hayvan tüyü(7/40) ve zeytin polenine (6/40) karşı olduğu görüldü. Yeni duyarlanma ABSTRACT Objective: Specific immunotherapy (SIT) is a well-established treatment method that is suggested to alter the natural course of the disease. Although the mechanisms remain unclear, recent studies have shown that allergen-specific immunotherapy may reduce the risk of new sensitizations. The aim of this study was to evaluate new sensitizations in children who underwent SIT for allergic airway diseases: allergic rhinitis, allergic asthma or both. Materials and Methods:This retrospective observational study was conducted at Behçet Uz Children's Hospital, among children with an allergic airway disorder due to monosensitization. The SIT group consisted 67 patients who had been offered, and accepted, and thus underwent SIT regularly during four years while the control group consisted of 57 patients who had been offered but refused SIT, and thus had not undergone SIT and were treated with medications only. The allergens that were negative at the first skin prick test but positive at the second prick test were accepted as 'new sensitization' . Results:The SIT group consisted of 67 (mean age ±SD: 15.27±3.15; Male /Female: 42/25) while the control group included 57 (mean age ± SD: 12.61 ± 2.69; Male /Female: 35/22) monosensitized patients with allergic airway disorder. There was no significant difference between SIT group and controls considering age and gender, current airway disease and current responsible allergen (p>0.05). The rate of new allergen sensitization in the immunotherapy group was 26/67 (38.8%) an...

show abstract

“…We requested Scientific Information Packages from industry representatives, but no information was provided. We also hand‐searched previous reviews and guidelines, searched http://ClinicalTrials.gov, and reviewed the FDA Adverse Event Reporting System (FAERS).…”

Section: Methodsmentioning

confidence: 99%

Role of sublingual immunotherapy in the treatment of asthma: An updated systematic review

Lin

Azar

Suarez‐Cuervo

et al. 2018

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

show abstract

Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review

Cited by 61 publications

References 48 publications

Allergen immunotherapy in people, dogs, cats and horses – differences, similarities and research needs

Allergen immunotherapy in people, dogs, cats and horses – differences, similarities and research needs

Does Allergen-Specific Immunotherapy Prevent New Sensitizations in Childhood Allergic Airway Diseases?

Role of sublingual immunotherapy in the treatment of asthma: An updated systematic review

Contact Info

Product

Resources

About